Hepcludex
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Bulevirtide
- Made by
- Gilead Sciences Ireland UC
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Hepcludex is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult and paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Gilead Sciences Ireland UC |
|---|---|
| Active substance | Bulevirtide |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05A · Antibiotics, antivirals and antifungals taken into the body |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2020-07-31 |
| Last updated by the regulator | 2026-03-31 |
| EMA product number | EMEA/H/C/004854 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).